Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451516 | 0.82 | TAAR1 (0.60) | TAAR1SLC6A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL272368 | 0.82 | TDP1 (0.48) | TAAR1SLC6A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL28681602 | 0.82 | SMN1; SMN2 (0.48) | TAAR1SLC6A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL251220 | 0.82 | TDP1 (0.48) | TAAR1SLC6A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL28112277 | 0.82 | TDP1 (0.48) | TAAR1SLC6A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21058237 | 0.82 | TAAR1 (0.54) | TAAR1SLC6A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL24950143 | 0.82 | TAAR1 (0.45) | TAAR1SLC6A2SMN1; SMN2CYP2A6HTR2A | |
| SCHEMBL4101648 | 0.80 | TAAR1 (0.44) | TAAR1SLC6A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7549612 | 0.80 | NPC1 (0.44) | TAAR1SLC6A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11853378 | 0.80 | TDP1 (0.39) | TAAR1NPC1RAB9ATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106471120-A | The method that anil is prepared from carbon source by fermentation method | 国立研究开发法人科学技术振兴机构 | 2017-03-01 | — | — | CN | disclosed |
| CN-106471120-A | The method that anil is prepared from carbon source by fermentation method | 国立研究开发法人科学技术振兴机构 | 2017-03-01 | — | — | CN | disclosed |
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | TAAR1 1355/4885SLC6A2 4716/4885SMN1; SMN2 4259/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | TAAR1 999/4885SLC6A2 4435/4885SMN1; SMN2 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.